Showing 1611-1620 of 1732 results for "".
- New Analysis from N-MOmentum Study Shows UPLIZNA Treatment Reduced Spinal Cord Lesion Formation in Patients with NMOSDhttps://practicalneurology.com/news/new-analysis-from-n-momentum-study-shows-uplizna-treatment-reduced-spinal-cord-lesion-formation-in-patients-with-nmosd/2470235/According to analysis of MRI data from the N-MOmentum clinical trial (NCT02200770), treatment with Uplizna (inebilizumab-cdon, Horizon Therapeutics PLC, Dublin, Ireland) reduced subclinical trans
- First Treatment for Genetic Form of Amyotrophic Lateral Sclerosis Approved by FDAhttps://practicalneurology.com/news/first-treatment-for-genetic-form-of-amyotrophic-lateral-sclerosis-approved-by-fda/2470172/The Food and Drug Administration (FDA) approved the first treatment for amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. Tofersen (QALSODY; Biogen, Cambridg
- Intramuscular Formulation of Depot Glatiramer Acetate, Dosed Monthly, Reduced Annualized Relapse Rate of Multiple Sclerosishttps://practicalneurology.com/news/glatiramer-acetate-reduces-annualized-relapse-rate-in-individuals-with-relapsing-multiple-sclerosis/2470030/In a phase 3 study (NCT04121221), a long acting glatiramer acetate (GA depot) (Mapi Pharma, Ziona, Israel) statistically significantly reduced the annualized relapse rate (ARR) by 30.1% compared with
- Cell and Gene Therapies for Parkinson Disease Moving Forwardhttps://practicalneurology.com/news/cell-and-gene-therapies-for-parkinson-disease-moving-forward/2469615/In an open-label phase 1 clinical study (NCT04802733), researchers successfully administered the first dose of pluripotent stem cell-derived dopaminergic neurons (DA01; Blue Rock Therapeutics, a subsidiery of Bayer Therapeutics, H
- Inebilizumab Provides Long-Term Freedom From Relapse for Neuromyelitis Optica Spectrum Disorderhttps://practicalneurology.com/news/inebilizumab-provides-long-term-freedom-from-relapse-for-neuromyelitis-optica-spectrum-disorder/2469562/Inebilizumab (Uplizna; Horizon Therapeutics, Deerfield, IL), an antiCD19 B cell depleteing antibody is approved by Food and Drug Administration for treatment of antiaquaporin-4 antibody positive (antiAQP4+) neuromyelitis optica spectrum disorder (NMOSD). In clinical trials, inebilizuma
- Cenobamate Provides High Rates of Seizure Freedom and Reductions or Discontinuations of Concomitant Antiseizure Medicationshttps://practicalneurology.com/news/cenobamate-provides-high-rates-of-seizure-freedom-and-reductions-or-discontinuations-of-concomitant-antiseizure-medications/2469559/Cenobamate was approved for treatment of partial onset seizures in May 2020 (Xcopri; SK LIfe Science, Paramus, NJ), and results of open-label extension studies have now been reported. Seizure reduction rates in the 214 people who had at least 1 dose of cenobamate after a 12-week titration period
- Neurovascular Quality Initiative-Quality Outcomes Database and the Society of Vascular and Interventional Neurology Form Alliancehttps://practicalneurology.com/news/neurovascular-quality-initiative-quality-outcomes-database-and-the-society-of-vascular-and-interventional-neurology-form-alliance/2469551/The Society of Neurointerventional Surgery (SNIS) and Neuropoint Alliance (NPA) will be bringing the Society of Vascular and Interventional Neurology (SVIN) to the Neurovascular Quality Initiative-Quality Outcomes Database (NVQI-QOD). The alliance is to expand the breadth and depth of the NVQI-QO
- Lasmiditan Provided Freedom From Migraine Pain at 60 Minutes for as Long as 48 Hourshttps://practicalneurology.com/news/lasmiditan-provided-freedom-from-migraine-pain-at-60-minutes-for-as-long-as-48-hours/2469375/In a phase 3 study (NCT02439320) of lasmiditan (Reyvow; Eli Lilly and Company, Indianapolis, IN), which is an approved treatment for migraine with or without aura, participants treated with
- Freedom from Pain and Most Bothersome Symptoms of Migraine With Ubrogepant in Phase 3 Trialhttps://practicalneurology.com/news/freedom-from-pain-and-most-bothersome-symptoms-of-migraine-with-ubrogepant-in-phase-3-trial/2469079/Positive results were achieved in the phase 3 clinical trial that evaluated ubrogepant (Allergan; Madison, NJ) for acute treatment of migraine. The data is published in The Journal of the American Medical Association
- Phase 3 Trial of Fenfluramine for Lennox-Gastaut Syndrome Completes Enrollmenthttps://practicalneurology.com/news/phase-3-trial-of-fenfluramine-for-lennox-gastaut-syndrome-completes-enrollment/2468948/Enrollment of 263 individuals with Lennox-Gastaut syndrome (LGS) has been completed for a phase 3 clinical (NCT03355209) trial of fenfluramine (Fintepla; Zogenix, Emeryville, CA). The primary outcome measure is decreased seizure freque